De novo pyrimidine synthesis is a collateral metabolic vulnerability in NF2-deficient mesothelioma.
Saved in:
| Title: | De novo pyrimidine synthesis is a collateral metabolic vulnerability in NF2-deficient mesothelioma. |
|---|---|
| Authors: | Xu D; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. xuduo@jsph.org.cn., Gao Y; Department of General Thoracic Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.; Department for BioMedical Research (DBMR), Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Liu S; Department of Cardiothoracic Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China., Yin S; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Hu T; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Deng H; Department of General Thoracic Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.; Department for BioMedical Research (DBMR), Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Zhang T; Department of General Thoracic Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.; Department for BioMedical Research (DBMR), Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Hegedüs B; Department of Thoracic Surgery, University Medicine Essen - Ruhrlandklinik, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Tüschener Weg 40, 45239, Essen, Germany., Marti TM; Department of General Thoracic Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.; Department for BioMedical Research (DBMR), Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Dorn P; Department of General Thoracic Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.; Department for BioMedical Research (DBMR), Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Liang SQ; Department of Medicine, University of Minnesota Twin Cities, 516 Delaware Street SE, Minneapolis, MN, USA., Schmid RA; Department of General Thoracic Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.; Department for BioMedical Research (DBMR), Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Peng RW; Department of General Thoracic Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Renwang.Peng@insel.ch.; Department for BioMedical Research (DBMR), Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Renwang.Peng@insel.ch., Shu Y; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. shuyongqian@csco.org.cn. |
| Source: | EMBO molecular medicine [EMBO Mol Med] 2025 Sep; Vol. 17 (9), pp. 2258-2298. Date of Electronic Publication: 2025 Jul 24. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: EMBO Press Country of Publication: Germany NLM ID: 101487380 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1757-4684 (Electronic) Linking ISSN: 17574676 NLM ISO Abbreviation: EMBO Mol Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
